RXRX - Recursion Pharmaceuticals

-

$undefined

N/A

(N/A)

Recursion Pharmaceuticals NasdaqGS:RXRX Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Location: 41 South Rio Grande Street, Salt Lake City, UT, 84101, United States | Website: https://www.recursion.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.403B

Cash

500.5M

Avg Qtr Burn

-97.21M

Short % of Float

26.82%

Insider Ownership

5.07%

Institutional Own.

75.94%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
REC-4881 Details
Familial Adenomatous Polyposis

Phase 2

Data readout

Phase 2

Data readout

REC-3964 Details
Clostridium difficile Colitis

Phase 2

Update

Phase 1/2

Data readout

REC-4539 Details
Small cell lung cancer, Cancer

Phase 1/2

Initiation

REC-3565 Details
R/R B-cell Lymphoma

Phase 1

Data readout

REC-617 Details
Solid tumor/s, Cancer

Phase 1

Update

REV102 Details
Hypophosphatasia (HPP)

Phase 1

Initiation

REC-2282 Details
Neurofibromatosis Type 2-mutated meningiomas

Failed

Discontinued

REC-3599 Details
GM2 gangliosidosis

Failed

Discontinued

REC-994 Details
Cerebral cavernous malformation

Failed

Discontinued